COVID-19 vaccines: breaking record times to first-in-human trials

The twenty-first century has come with a new era in vaccinology, in which recombinant genetic technology has contributed to setting an unprecedented fast pace in vaccine development, clearly demonstrated during the recent COVID-19 pandemic.

Detalles Bibliográficos
Autores principales: Kim, Young Chan, Dema, Barbara, Reyes-Sandoval, Arturo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Comment
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7193619/
https://www.ncbi.nlm.nih.gov/pubmed/32377399
http://dx.doi.org/10.1038/s41541-020-0188-3
_version_ 1783528228721262592
author Kim, Young Chan
Dema, Barbara
Reyes-Sandoval, Arturo
author_facet Kim, Young Chan
Dema, Barbara
Reyes-Sandoval, Arturo
author_sort Kim, Young Chan
collection PubMed
description The twenty-first century has come with a new era in vaccinology, in which recombinant genetic technology has contributed to setting an unprecedented fast pace in vaccine development, clearly demonstrated during the recent COVID-19 pandemic.
format Online
Article
Text
id pubmed-7193619
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-71936192020-05-06 COVID-19 vaccines: breaking record times to first-in-human trials Kim, Young Chan Dema, Barbara Reyes-Sandoval, Arturo NPJ Vaccines Comment The twenty-first century has come with a new era in vaccinology, in which recombinant genetic technology has contributed to setting an unprecedented fast pace in vaccine development, clearly demonstrated during the recent COVID-19 pandemic. Nature Publishing Group UK 2020-04-30 /pmc/articles/PMC7193619/ /pubmed/32377399 http://dx.doi.org/10.1038/s41541-020-0188-3 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Comment
Kim, Young Chan
Dema, Barbara
Reyes-Sandoval, Arturo
COVID-19 vaccines: breaking record times to first-in-human trials
title COVID-19 vaccines: breaking record times to first-in-human trials
title_full COVID-19 vaccines: breaking record times to first-in-human trials
title_fullStr COVID-19 vaccines: breaking record times to first-in-human trials
title_full_unstemmed COVID-19 vaccines: breaking record times to first-in-human trials
title_short COVID-19 vaccines: breaking record times to first-in-human trials
title_sort covid-19 vaccines: breaking record times to first-in-human trials
topic Comment
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7193619/
https://www.ncbi.nlm.nih.gov/pubmed/32377399
http://dx.doi.org/10.1038/s41541-020-0188-3
work_keys_str_mv AT kimyoungchan covid19vaccinesbreakingrecordtimestofirstinhumantrials
AT demabarbara covid19vaccinesbreakingrecordtimestofirstinhumantrials
AT reyessandovalarturo covid19vaccinesbreakingrecordtimestofirstinhumantrials

Ejemplares similares